The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Open accessAbstract
Purpose: Complete response (CR) is considered an important goal in most hematologic malignancies. However, in multiple myeloma (MM), there is no consensus regarding whether immunofixation (IF)-negative CR, IF-positive near-CR (nCR), and partial response (PR) are associated with different survivals. We evaluated the prognostic influence on event-free survival (EFS) and overall survival (OS) of these responses pre- and post-transplantation in newly diagnosed patients with MM. Patients and Methods: We analyzed 632 patients from the prospective Grupo Español de Mieloma 2000 protocol who were uniformly treated with vincristine, carmustine, cyclophosphamide, melphalan, and predisone/vincristine, carmustine, adryamcine, and dexamethasone induction followed by high-dose therapy and autologous stem-cell transplantation. Results: Post-transplantation response markedly influenced outcomes. Patients achieving CR had significantly longer EFS (median, 61 v 40 months; P < 10 −5 ) and OS (medians not reached; P = .01) versus patients achieving nCR, who likewise had somewhat better outcomes compared with patients achieving PR (median EFS, 34 months, P = .07 v nCR; median OS, 61 months, P = .04). EFS and OS and influence of response were similar among older (age 65 to 70 years) and younger (age < 65 years) patients. Similar findings were observed with pretransplantation response, with trends toward EFS (P = .1; P = .05) and OS (P = .1; P = .07) benefit in patients achieving CR versus nCR and PR, respectively. Post-transplantation response was markedly influenced by pretransplantation response; improvements in response were associated with prolonged survival. Conclusion: Quality of response post-transplantation, notably CR, is significantly associated with EFS and OS prolongation in newly diagnosed patients with MM. There were trends toward similar associations with pretransplantation response status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Self-citationSingle versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Facon, T., Mary, J. Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 869
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053583 · Cited by 739
Pasquali, S., Maqueo, J. D., Vela, J. E., Kyle, R. A., Leong, T. L., Fritz, E., Suciu, S., PALVA, I. P., Oivanen, T. M., Corrado, C., et al. (1998) · Journal of Clinical Oncology · Cited by 470
Self-citation(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
Fermand, J.-P., Katsahian, S., Divine, M., Leblond, V., Dreyfus, F., Macro, M., Arnulf, B., Royer, B., Mariette, X., Pertuiset, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0551 · Cited by 399
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma
Barlogie, B., Hall, R., Zander, A., Dicke, K., & Alexanian, R. (1986) · Blood · doi:10.1182/blood.v67.5.1298.1298 · Cited by 340
van de Velde, H. J. K., Liu, X., Chen, G., Cakana, A., Deraedt, W., & Bayssas, M. (2007) · Haematologica · doi:10.3324/haematol.11534 · Cited by 283
Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma
Siegel, D. S., Desikan, K. R., Mehta, J., Singhal, S., Fassas, A., Munshi, N., Anaissie, E., Naucke, S., Ayers, D., Spoon, D., et al. (1999) · Blood · doi:10.1182/blood.v93.1.51 · Cited by 239
Liu, Y., Pop, R., Sadegh, C., Brugnara, C., Haase, V. H., & Socolovsky, M. (2006) · Blood · doi:10.1182/blood-2005-11-4458 · Cited by 216
Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan, J., Viner, C., & Malpas, J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.759 · Cited by 214
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Sarasquete, M. E., García‐Sánz, R., González, D., Martínez‐López, J., Mateo, G., Martı́nez, P., Ribera, J., Hernández, J. M., Lahuerta, J. J., Órfão, A., et al. (2005) · PubMed · Cited by 181
Self-citationSan Miguel, J. F., Almeida, J., Mateo, G., Bladé, J., López-Berges, C., Caballero, D., Hernández, J., Moro, M. J., Fernández-Calvo, J., Dı́az-Mediavilla, J., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1853 · Cited by 160
Self-citationRajkumar, S. V., Jacobus, S. J., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S. D., & Greipp, P. T. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.lba8025 · Cited by 145
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
Alexanian, R., Weber, D., Giralt, S., Dimopoulos, M. A., Delasalle, K. B., Smith, T., & Champlin, R. E. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703035 · Cited by 135
O’Shea, D., Giles, C. M., Terpos, E., Perz, J. B., Politou, M., Sana, V., Naresh, K. N., Lampert, I. A., Samson, D., Narat, S., et al. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705307 · Cited by 108
Lahuerta, J. J., Martínez‐López, J., de la Serna, J., Bladé, J., Grande, C., Alegre, A. M., Vázquez, L., García‐Laraña, J., Sureda, A. M., de la Rubia, J., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02012.x · Cited by 107
Self-citationRajkumar, S. V., Jacobus, S. J., Callander, N. S., Fonseca, R., Vesole, D. H., & Greipp, P. R. (2006) · Blood · doi:10.1182/blood.v108.11.799.799 · Cited by 107
Cavo, M., Terragna, C., Martinelli, G., Ronconi, S., Zamagni, E., Tosi, P., Lemoli, R. M., Benni, M., Pagliani, G., Bandini, G., et al. (2000) · Blood · doi:10.1182/blood.v96.1.355 · Cited by 100
Carreras, E., Rosiñol, L., Terol, M. J., Alegre, A. M., de Arriba, F., García‐Laraña, J., Belló, J., García, R., León, Á., Martínez, R., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.08.002 · Cited by 93
Self-citationTransplantation for multiple myeloma: who, when, how often?
(2003) · Blood · doi:10.1182/blood-2003-01-0073 · Cited by 88
Self-citationZonder, J. A., Crowley, J. J., Hussein, M. A., Bolejack, V., Moore, D. F., Whittenberger, B. F., Abidi, M. H., Durie, B. G. M., & Barlogie, B. (2007) · Blood · doi:10.1182/blood.v110.11.77.77 · Cited by 83
Harousseau, J. L., Mathiot, C., Attal, M., Marit, G., Caillot, D., Mohty, M., Hulin, C., Facon, T. T. F., Webb, I. I. W., & Moreau, P. (2007) · Blood · doi:10.1182/blood.v110.11.450.450 · Cited by 82
Cavo, M., Patriarca, F. F., Tacchetti, P., Galli, M., Perrone, G., Petrucci, M. T., Brioli, A., Bringhen, S., Pantani, L., Tosi, P., et al. (2007) · Blood · doi:10.1182/blood.v110.11.73.73 · Cited by 77
Harousseau, J., Marit, G., Caillot, D., Casassus, P., Facon, T. T. F., Mohty, M., Maloisel, F., Maisonneuve, H., Chaleteix, C., Benboubker, L., et al. (2006) · Blood · doi:10.1182/blood.v108.11.56.56 · Cited by 75
Lenhoff, S., Hjorth, M., Turesson, I., Westin, J., Gimsing, P., Wislöff, F., Ahlberg, L., Carlson, K. E., Christiansen, I., Dahl, I. M. S., et al. (2006) · PubMed · Cited by 72
Martínez‐Sánchez, P., Montejano, L., Sarasquete, M. E., García‐Sánz, R., Fernández‐Redondo, E., Ayala, R. M., Montalbán, M.-Á., Martínez, R., Laraña, J. G., Alegre, A. M., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07263.x · Cited by 62
Self-citationMouse plasmacytoid dendritic cells derive exclusively from estrogen-resistant myeloid progenitors
Harman, B. C., Miller, J. P., Nikbakht, N., Gerstein, R. M., & Allman, D. (2006) · Blood · doi:10.1182/blood-2005-11-4545 · Cited by 57
de la Rubia, J., Bladé, J., Lahuerta, J.-J., Ribera, J., Martínez, R., Alegre, A. M., García‐Laraña, J., Fernández, P., Sureda, A. M., de Arriba, F., et al. (2006) · PubMed · Cited by 56
Self-citationAlvares, C. L., Davies, F. E., Horton, C., Patel, G. W., Powles, R., Sirohi, B., Zuha, R., Gatt, A., Saso, R. M., Treleaven, J. G., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05514.x · Cited by 49
Relationship Between Depth of Response and Outcome in Multiple Myeloma
Dingli, D., Pacheco, J. M., Nowakowski, G. S., Kumar, S. K., Dispenzieri, A. A., Hayman, S. R., Lacy, M. Q., Gastineau, D. A., & Gertz, M. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7879 · Cited by 45
Majolino, I., Vignetti, M., Meloni, G., Vegna, M. L., Scimè, R., Tringali, S., Amaddii, G., Coser, P., Tribalto, M., Raimondi, R., et al. (1999) · PubMed · Cited by 37
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Galli, M., Nicolucci, A., Valentini, M., Belfiglio, M., Delaini, F., Crippa, C., Barbui, A. M., Giussani, U., Rambaldi, A., & Barbui, T. (2005) · PubMed · Cited by 18
Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy.
Corso, A., Nozza, A., Lazzarino, M., et al. (1999) · PubMed · Cited by 14
Eliminating the complete response penalty from myeloma response assessment
Lonial, S., & Gertz, M. A. (2008) · Blood · doi:10.1182/blood-2008-01-132456 · Cited by 13
Current Treatment Strategies for Multiple Myeloma
Thomas, S. K., & Alexanian, R. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.014 · Cited by 9
Cited by
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Flores-Montero, J., Sanoja-Flores, L., Paiva, B., Puig, N., García-Sánchez, O., Böttcher, S., van der Velden, V. H. J., Pérez-Morán, J.-J., Vidriales, M.-B., García-Sanz, R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.29 · Cited by 676
Self-citationRöllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
IMWG consensus on risk stratification in multiple myeloma
Chng, W. J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N., Palumbo, A., Miguel, J. S., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2013.247 · Cited by 601
Metadata
- Authors
- Lahuerta, J. J., Mateos, M. V., Martínez-López, J., Rosiñol, L., Sureda, A., de la Rubia, J., García-Laraña, J., Martínez-Martínez, R., Hernández-García, M. T., Carrera, D., Besalduch, J., de Arriba, F., Ribera, J. M., Escoda, L., Hernández-Ruiz, B., García-Frade, J., Rivas-González, C., Alegre, A., Bladé, J., & San Miguel, J. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-12-10
- Volume
- 26
- Issue
- 35
- Pages
- 5775-5782
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2150254829
- Cited by
- 279
- References
- 45
- FWCI
- 15.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.